Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Ketamine/Traumatic Brain Injury (TBI)

Ketamine for Traumatic Brain Injury (TBI)

1 paper and 8 clinical trials exploring ketamine as a treatment for traumatic brain injury (tbi).

CompoundArylcyclohexylamine

Ketamine

A dissociative anesthetic with rapid-acting antidepressant properties, widely used in clinical settings for mood and pain disorders.

Full Ketamine profile
IndicationApproximately 70 million individuals worldwide sustain a TBI each year.

Traumatic Brain Injury (TBI)

Psychedelics are being investigated for their potential therapeutic effects on Traumatic Brain Injury (TBI), a condition that frequently results in various physical and psychological impairments. Early preclinical studies suggest that these compounds may influence inflammatory responses, promote neuroplasticity, and enhance neurogenesis, offering new avenues for treatment.

Full Traumatic Brain Injury (TBI) profile

Academic Research

1 paper
Open Accessindividual

Outcomes and physiologic responses associated with ketamine administration after traumatic brain injury in the United States and Canada: a retrospective analysis

Ketamine administration after traumatic brain injury was not associated with increased mortality or greater disability despite being given to more severely injured patients. Ketamine exposure correlated with fewer episodes of elevated intracranial pressure and smaller rises in TBI protein biomarkers, but a higher incidence of seizures and, in the intracranial haemorrhage subgroup, more cardiac events.

Published
December 31, 2023
Journal
Journal of Trauma Injury Infection and Critical Care
Authors
Peters, A. J., Khan, S. A., Koike, S., Rowell, S., Schreiber, M.

Clinical Trials

8 trials
RecruitingPhase II

Ketamine, SGB and Combination Treatment for TBI

This randomised, double-blind, placebo-controlled trial (n=175) will investigate the efficacy of stellate ganglion block (SGB) and ketamine infusion, both separately and in combination, in treating PTSD and TBI-associated headache.

Started
February 15, 2025
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
NCT06608277
Temporarily not availablePhase IV

Ketamine for Sedation in Severe Traumatic Brain Injury (Ketamine)

This open-label randomized trial (n=50) will assess the safety of ketamine plus propofol sedation versus standard-of-care analgosedation in ICU patients with severe TBI.

Started
June 1, 2024
Type
interventional
Blinding
none
Randomized
Yes
Registry ID
NCT06429657
Not yet recruitingPhase II

Ketamine Treatment for PTSD and MDD in TBI

Randomised, quadruple-blind, parallel Phase II trial (n=40) comparing IV ketamine 0.5 mg/kg vs midazolam 0.045 mg/kg twice weekly for 3 weeks in Veterans with mild–moderate TBI and comorbid PTSD and MDD to evaluate efficacy and safety.

Started
March 1, 2024
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT06228391
RecruitingPhase I

Ketamine in Severe Traumatic Brain Injury

This early Phase I interventional trial (n=10) will assess the neurophysiological effect of ketamine in patients with severe Traumatic Brain Injury (TBI).

Started
February 1, 2024
Type
interventional
Blinding
none
Randomized
No
Registry ID
NCT06062628
Unknown statusPhase NA

Reversal of Battle-Related Aging (ROBRA) in a Special Operations Forces Cohort

This observational cohort study (n=20) aims to investigate the impact of a combined protocol of subanesthetic ketamine infusions (SKI) and bilateral cervical sympathetic blocks (CSB) on ageing in Special Operations Forces (SOF) members undergoing treatment for PTSD/TBI.

Started
July 5, 2023
Type
observational
Randomized
No
Registry ID
NCT05855876
RecruitingPhase IV

Ketamine in Acute Brain Injury Patients

This double-blind, placebo-controlled randomized multicentre clinical trial (n=100) aims to investigate the safety and feasibility of using ketamine as an adjunct to a standard sedative strategy in Traumatic Brain Injury (TBI) patients.

Started
September 6, 2021
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
NCT05097261

Explore further

Search all Ketamine papers Search all Traumatic Brain Injury (TBI) trials Full Ketamine profile Full Traumatic Brain Injury (TBI) profile